My impression is that the oncology community has jumped on this category of drugs in lieu of tamoxifen in a huge number of people much too quickly. When aromatase inhibitors first came out and were tested, it was stage 3 and 4 women. Survival was clearly better than with tamoxifen. Now they're giving it to all these women with stage 1 and stage 0 cancer, who are likely to be cured, and they have no long-term data. Steven Goldstein